Abstract Number: 676 • 2013 ACR/ARHP Annual Meeting
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease
Background/Purpose: To investigate whether patients affected with any of the 3 subsets of early systemic sclerosis (SSc) i.e. Raynaud’s Phenomenon (RP) with SSc marker autoantibody…Abstract Number: 683 • 2013 ACR/ARHP Annual Meeting
HRCT Predictors Of Decline In FVC% predicted—Implications For Cohort Enrichment For Scleroderma Lung Disease (SLD) Trials
Background/Purpose: Moderate-to-severe HRCT-defined lung involvement (total lung involvement or fibrosis) is a predictor of decline in FVC% predicted and mortality in SLD. Various staging systems…Abstract Number: 1467 • 2012 ACR/ARHP Annual Meeting
Association of Gastroesophageal Factors and Progression of Interstitial Lung Disease in the Canadian Scleroderma Research Group, a Large, Multicenter Database
Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is a leading contributor to mortality in SSc patients. Once lung…Abstract Number: 125 • 2012 ACR/ARHP Annual Meeting
Borderline Right Ventricular Involvement in Patients with Systemic Sclerosis without Pulmonary Hypertension
Background/Purpose: Cardiac dysfunction in systemic sclerosis (SSc) is associated with poor prognosis. Right ventricular involvement is tipically associated to pulmonary hypertension (PH) in these patients.…Abstract Number: 94 • 2012 ACR/ARHP Annual Meeting
Medical Costs and Health Care Resource Use in Patients with Systemic Sclerosis in an Insured Population
Background/Purpose: Systemic sclerosis (SSc) is a chronic connective tissue disease affecting the skin and/or internal organs. Data on US economic burden of SSc is scant…Abstract Number: 2307 • 2012 ACR/ARHP Annual Meeting
Role of Endosomal and Cell Membrane Toll-Like Receptors in Keratinocyte Activation by Systemic Sclerosis Autoantibodies
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune rare connective tissue disorder of unknown aetiology, heterogeneous clinical manifestations and an often progressive course which includes skin…Abstract Number: 2287 • 2012 ACR/ARHP Annual Meeting
Altered Regulation of Metabolic Pathways in Systemic Sclerosis Evidenced by Metabolomics
Background/Purpose: High throughput study of metabolic pathways might help identify new biomarkers and therapeutic targets in autoimmune diseases. Systemic sclerosis (SSc) currently lacks prognostic biomarkers…Abstract Number: 2292 • 2012 ACR/ARHP Annual Meeting
Increased Synthesis of Leukotrienes by Peripheral Blood Mononuclear Cells Is Associated with More Severe Disease and Worse Prognosis in Patients with Systemic Sclerosis
Background/Purpose: Eicosanoids are a group of arachidonic acid-derived lipid mediators which play a key role in the regulation of inflammatory response and connective tissue remodeling.…Abstract Number: 2298 • 2012 ACR/ARHP Annual Meeting
The Arachidonate 5-Lipoxygenase Activating Protein (ALOX5AP) Polymorphism Is Associated with Risk of Scleroderma-Related Interstitial Lung Disease: A Multicenter Study From the EULAR Scleroderma Trial and Research Group
Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune disease characterized by chronic inflammation, vascular injury and profound fibrosis of the skin and internal organ. Leukotrienes…Abstract Number: 1714 • 2012 ACR/ARHP Annual Meeting
Gender Differences in Systemic Sclerosis: Relationship to Disease Specific Clinical Manifestations and Estradiol Levels
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by inflammation, autoantibody production, and increased production of extracellular matrix (ECM), resulting in fibrosis. We…Abstract Number: 1716 • 2012 ACR/ARHP Annual Meeting
Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis
Background/Purpose: A number of clinical trials using intensive immunosuppression followed by autologous haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) are underway or have…Abstract Number: 1521 • 2012 ACR/ARHP Annual Meeting
A Possible Contribution of Decreased Cathepsin V Expression to the Development of Dermal Fibrosis, Proliferative Vasculopathy, and Altered Keratinocyte Phenotype in Systemic Sclerosis
Background/Purpose: Cathepsin V (CTSV) is a proteolytic enzyme potentially modulating angiogenic processes, collagen degradation, and keratinocyte differentiation. Although our latest paper demonstrated that cathepsin B,…Abstract Number: 1478 • 2012 ACR/ARHP Annual Meeting
Gender-Associated Differences in Disease Characteristics and Outcome in Systemic Sclerosis
Background/Purpose: Although significant female gender predominance is seen in majority of large systemic sclerosis (SSc) cohorts, multiple studies have suggested that male gender generally associates…Abstract Number: 1480 • 2012 ACR/ARHP Annual Meeting
The 15% Rule in Scleroderma: A Systematic Review of the Frequency of Organ Complications in Systemic Sclerosis
Background/Purpose : The prevalence of each organ complication in scleroderma (SSc) varies by definition used. However, it is important to be aware of several complications…Abstract Number: 1485 • 2012 ACR/ARHP Annual Meeting
Patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS) Present Esophageal and Anorectal Involvement: Data From a Single Centre
Background/Purpose: Systemic Sclerosis (SSc) affects gastrointestinal tract in more than 80% of patients. Esophageal involvement is the most common manifestation with a prevalence ranging between…
